Roche sues Intas Pharma over patent dispute in India
Roche Pharmaceuticals is suing Indian-based Intas Pharmaceuticals, alleging that the company has infringed upon its patent rights to anaemia drug, Mircera, in the country.
Mircera is an injectable drug used to treat patients with anaemia in chronic-kidney related conditions. It accounts for up to $500 million in global sales for the Swiss pharmaceutical firm.
Speaking to the Economic Times in India, Intas issued a statement claiming that they “also have strong grounds for invalidation of the enforced statement. Intas has launched its own product under the brand name Erypeg at a lower price to Roche’s Mircera, at the same dosage.
This is not the first time that Roche has brought proceedings against Intas in a patent dispute. In 2013, a court ruled in favour of the latter in a dispute related to Roche’s non-small cell lung cancer treatment, Tarceva (erlotinib hydrochloride).
According to the Economics Times, Roche has sought an injunction order against the Erypeg brand, but no decision has yet been taken.
GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the …
Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …